American Society of Hirudotherapy

Lyfjastofnun — Icelandic Medicines Agency

IMA · Iceland · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Iceland's Medicines Agency — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the EEA-aligned medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Iceland
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Icelandic national implementing legislation for Regulation (EU) 2017/745 (MDR) via the EEA Agreement
  • Icelandic Medicines Act

Prescriber Requirements

  • Icelandic-licensed physician (læknir) registered with the Directorate of Health — order required for any device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Distributors operate under EEA-aligned MDR economic-operator obligations; standard cold-chain conditions for live invertebrates. Icelandic-language IFU.

Import/Export Rules

EEA free movement applies; third-country imports require CITES Appendix II paperwork for Hirudo medicinalis / verbana and Icelandic Food and Veterinary Authority (MAST) clearance for live invertebrates.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Iceland participates in EU medicines and devices law via the EEA Agreement rather than EU membership.

Related Jurisdictions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.